Novartis sees no coronavirus disruption amid China growth
Share:
BASEL, Switzerland (Reuters) - Novartis is not seeing any disruption to its supply chain due to the coronavirus outbreak, CEO Vas Narasimhan said on Wednesday, as the Swiss drugmaker predicted rising sales and profit in 2020, including from its growing Chinese market. Fourth-quarter core net income rose to $2.99 billion (2.27 billion pounds), a 13% rise in constant currencies, as its new Zolgensma gene therapy gained traction and sales of five-year-old drugs Cosentyx and Entresto continued to..